Flores SG

Language: Spanish
References: 22
Page: 43-49
PDF size: 417.23 Kb.

ABSTRACT

Venous thromboembolic disease is rarely associated with hereditary thrombophilia, which can be classified into two main categories: loss of function mutations (antithrombin III, protein C, protein S) and gain-of-function mutations (prothrombin gene mutation). G20210A), MTHFR mutation, Factor VIII, Factor V Leiden). We present the case of a young man with chronic thromboembolic pulmonary hyperten sion (CTEPH) and heterozygosity in the MTHFR gene, which exemplifies the possibility of assessing this pathology in a specialized medical consultation that is not vascular, hematological or rheumatological; and given the clinical evolution and high medical care costs of these patients, justifies the review of the etiopathogenesis and clinical consequences of this polymorphism, which causes a homocysteinemethionine imbalance that influences reactions of cell proliferation, protein synthesis, synthesis of RNA and methylation processes of DNA and other substances at the cellular level. However, its association with thromboembolism is controversial and it has not been possible to confirm a significant association between hereditary thrombophilia and CTEPH. Complications such as that presented in the case described with the development of right heart failure, in a patient not endarterectomy tributary, acquire legal and ethical medical relevance, not only because of the possibility of prescribing medical treatment and its cost for social security, but also because its effect on survival, which demonstrates the importance of studies for the development of new prophylactic and therapeutic drugs and genetic counseling in cases of a genetically determined tendency to venous thromboembolic disease.

REFERENCES

1. Lee SY Kim EK Kim MS et al. The prevalence and clinical manifestation of hereditary thrombophilia in Korean patients with unprovoked venous thromboembolisms. PLoS One. 2017; 12(10):e0185785. doi: 10.1371/journal.pone.0185785. eCollection 2017.

2. Liu F Silva D Malone MV Seetharaman K. MTHFR A1298C and C677T Polymorphisms Are Associated with Increased Risk of Venous Thromboembolism: A Retrospective Chart Review Study. Acta Haematol. 2017; 138(4):208-215. doi: 10.1159/000480447. Epub 2017 Dec 7

3. Xu J Li K Zhou W. Relationship between genetic polymorphism of MTHFR C677T and lower extremities deep venous thrombosis. Hematology. 2018:1-4. doi: 10.1080/10245332.2018.1526440. [Epub ahead of print]

4. Castañeda R Munive M Meillón LA Rish L Sigler L Prieto P. Trombosis venosa asociada a trombofilias. Revisión y reporte de casos. Rev Mex Angiol 2017; 45(2): 73-79.

5. Ehsani M Imani A Moravveji A. Prevalence of factor V leiden, MTHFR C677T and MTHFR A1298C polymorphisms in patients with deep vein thrombosis in Central Iran. Mol Biol Rep. 2018; 45(4):621-624. doi: 10.1007/s11033-018-4201-0. Epub 2018 May 31.

6. Grand B Rossi A. Solicitud inapropiada de estudios y sobrediagnóstico de trombofilia: exigen estudiar más polimorfismos. El nuevo proyecto de ley. Hematología. 2017; 21(2): 237-240.

7. Bezgin T Kaymaz C Akbal Ö Yılmaz F Tokgöz HC Özdemir N. Thrombophilic Gene Mutations in Relation to Different Manifestations of Venous Thromboembolism: A Single Tertiary Center Study. Clin Appl Thromb Hemost. 2018; 24(1):100-106. doi: 10.1177/1076029616672585. Epub 2016 Oct 11.

8. Hotoleanu C. Genetic Risk Factors in Venous Thromboembolism. Adv Exp Med Biol. 2017; 906:253- 272. doi: 10.1007/5584_2016_120

9. Moreira S Gonçalves M Gaspar E Santos L. Recurrent Venous Thrombosis: Is there a Place for Methylenetetrahydrofolate Reductase Polymorphisms? JOJ Case Stud. 2018; 7(2): 555709. doi: 10.19080/JOJCS. 2018.07.555709.

10. Vizcaíno G Vizcaíno J. Homocisteína: bases genéticas y sus implicaciones cardiovasculares y cognitivas como factor de riesgo. Invest Clin. 2017; 58(4): 406-436.

11. Sierra C Moretó A Iruín G Martín X García JC. Protocolo diagnóstico de la trombofilia. Medicine 2016; 12(22):1299-1303.

12. Brandimarti F Alessandrini F Pesaresi M et al. Investigation on genetic thrombophilic factors in FFPE autopsy tissue from subjects who died from pulmonary embolism. Int J Legal Med. 2017;131(2):447-458. doi: 10.1007/s00414-016-1508-z. Epub 2016 Dec 9.

13. Froese DS Huemer M Suormala T et al. Mutation Update and Review of Severe Methylenetetrahydrofolate Reductase Deficiency. Hum Mutat. 2016; 37(5):427-38. doi: 10.1002/humu.22970. Epub 2016 Mar 18.

14. Nefic H Mackic-Djurovic M Eminovic I. The Frequency of the 677C>T and 1298A>C Polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in the Population. Med Arch. 2018; 72(3):164- 169. doi: 10.5455/medarh.2018.72.164-169

15. Cacciapuoti F. Poor re-Methylation of Homocysteine and Trans-Methylation of Methionine: Cause and Effect of Hyper-Homocysteinemia: Which Role for Folic Acid and Vitamins B-6-12 Supplementation? Ann Clin Exp Metabol. 2018; 3(1): 1026.

16. Levin BL Varga E. MTHFR: Addressing Genetic Counseling Dilemmas Using Evidence-Based Literature. J Genet Couns.2016; 25(5):901-11. doi: 10.1007/ s10897-016-9956-7. Epub 2016 Apr 30.

17. Dean L. Methylenetetrahydrofolate Reductase Deficiency. 2012 Mar 8 [Updated 2016 Oct 27] In: Pratt V, McLeod H, Rubinstein W, et al, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. p. 487-491. Available from: https://www.ncbi. nlm.nih.gov/books/NBK66131/ .

18. Gao L Kolanuvada B Naik G et al. Hyperhomocysteinemia- induced upper extremity deep vein thrombosis and pulmonary embolism in a patient with methyltetrahydrofolate reductase mutation: a case report and literature review. Blood Coagul Fibrinolysis. 2016; 27(6):720-3. doi: 10.1097/MBC.0000000000000458.

19. Rommer PS Zschocke J Fowler B et al. Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency. J Neurol Sci. 2017; 383:123-127. doi: 10.1016/j.jns.2017.10.035. Epub 2017 Nov 6.

20. Malo M. Variantes Genéticas de Trombofilia en Pacientes Jóvenes con Enfermedad Tromboembólica Venosa [Tesis Doctoral]. Zaragoza (España): Universidad de Zaragoza; 2016.

21. Maldonado L Bosio M Salvado A Chertcoff J. Hipertensión pulmonar tromboembólica crónica. RAMR 2016; 16(4): 302-311.

22. McLaughlin VV Jansa P Nielsen-Kudsk JE et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med. 2017; 17(1):216. doi: 10.1186/ s12890-017-0563-7.